Lessons from the diagnosis and treatment of severe immune checkpoint inhibitor-associated pneumonia: a case report.
Fengxia WengJianhua WeiMing SangXin GaoPing ZhangQinghui FuPublished in: Immunotherapy (2023)
Herein, we report a case of an elderly male patient who underwent extended radical resection of cardiac carcinoma after regular chemotherapy combined with sintilimab (PD-1 monoclonal antibody) immunotherapy complicated with severe pneumonitis postoperatively. We performed several treatments for aspiration pneumonitis; however, the patient's pulmonary infection and oxygenation were not efficiently improved. The multidisciplinary team considered it an immune checkpoint inhibitor-associated pneumonitis after diagnosis and treatment and then modified the treatment regimen. The pulmonary inflammation was effectively controlled with improved oxygenation; the patient was gradually weaned from the ventilator and finally discharged. The possibility of immune checkpoint inhibitor-associated pneumonitis should be fully considered particularly for patients with a history of immunosuppressive therapy with clinical symptoms of severe pneumonitis.
Keyphrases
- interstitial lung disease
- monoclonal antibody
- case report
- pulmonary hypertension
- early onset
- oxidative stress
- palliative care
- left ventricular
- drug induced
- stem cells
- intensive care unit
- heart failure
- blood flow
- acute respiratory distress syndrome
- radiation therapy
- rectal cancer
- mechanical ventilation
- extracorporeal membrane oxygenation
- physical activity
- replacement therapy